The global Liquid Biopsy Market size is expected to reach USD 5.96
billion by 2030, according to a new report by Grand View Research, Inc.,
exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor
provided by liquid biopsy technology is estimated to augment the market in
coming years.
While tissue biopsies have been standard for cancer
diagnosis for past several year, their highly invasive nature and frequently
associated complications have been major concerns. Moreover, these biopsies
lead to high expenditure being incurred by patients. Liquid biopsies, on the
other hand, offer a less invasive methodology along with high effectiveness.
Thus, there are a number of key private organizations involved in rigorous
R&D activities for liquid biopsy test development and it is only a matter
of time before these procedures grow in prominence in diagnostic paraphernalia
of oncologists and pathologists.
Further key findings from the report suggest:
- Technological developments such as electric field induced release
and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection
that can assist clinical treatment decisions for most common subtype of
cancers are expected to drive the uptake of saliva based sampling over the
forecast period
- Currently, clinical use of isolation and detection technology is
limited to CTC quantitation but the number of CTCs is found to hold
significant correlation with disease severity. This is, thus, estimated to
augment the market over the coming years
- Rising awareness regarding advantages of multiple gene analysis
along with the help of NGS is anticipated to support the growth of the
market
- Organizations such as American Society of Clinical Oncology (ASCO)
are engaged in supporting implementation of liquid biopsy, which in turn
is likely to spur the growth of the market
- Intensifying competition between biotech companies and increasing
investments by government in healthcare institutes will lead to
development of more sophisticated tests
- Companies engaged in R&D and commercialization of these
products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina;
Foundation Medicine; Roche; LabCorp; and Sequenom
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment